GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Shiller PE Ratio

Insulet (Insulet) Shiller PE Ratio : (As of Apr. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Insulet Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Insulet Shiller PE Ratio Historical Data

The historical data trend for Insulet's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Shiller PE Ratio Chart

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insulet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Insulet's Shiller PE Ratio

For the Medical Devices subindustry, Insulet's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Insulet's Shiller PE Ratio falls into.



Insulet Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Insulet's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Insulet's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.44/129.4194*129.4194
=1.440

Current CPI (Dec. 2023) = 129.4194.

Insulet Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.110 99.695 -0.143
201406 -0.530 100.560 -0.682
201409 -0.190 100.428 -0.245
201412 -0.100 99.070 -0.131
201503 -0.210 99.621 -0.273
201506 -0.270 100.684 -0.347
201509 -0.340 100.392 -0.438
201512 -0.480 99.792 -0.623
201603 -0.220 100.470 -0.283
201606 -0.080 101.688 -0.102
201609 -0.050 101.861 -0.064
201612 -0.160 101.863 -0.203
201703 -0.170 102.862 -0.214
201706 -0.130 103.349 -0.163
201709 -0.040 104.136 -0.050
201712 -0.120 104.011 -0.149
201803 -0.112 105.290 -0.138
201806 -0.030 106.317 -0.037
201809 0.030 106.507 0.036
201812 0.160 105.998 0.195
201903 0.070 107.251 0.084
201906 0.020 108.070 0.024
201909 0.010 108.329 0.012
201912 0.080 108.420 0.095
202003 -0.030 108.902 -0.036
202006 0.220 108.767 0.262
202009 0.170 109.815 0.200
202012 -0.260 109.897 -0.306
202103 0.000 111.754 0.000
202106 -0.370 114.631 -0.418
202109 0.180 115.734 0.201
202112 0.420 117.630 0.462
202203 0.400 121.301 0.427
202206 -0.500 125.017 -0.518
202209 -0.080 125.227 -0.083
202212 0.240 125.222 0.248
202303 0.340 127.348 0.346
202306 0.390 128.729 0.392
202309 0.740 129.860 0.737
202312 1.440 129.419 1.440

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Insulet  (NAS:PODD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Insulet Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Insulet's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (Insulet) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Executives
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche officer: SVP, Global Manufacturing C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen officer: SVP and CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears officer: SVP, Quality and Regulatory C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine director C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730

Insulet (Insulet) Headlines

From GuruFocus

Insulet Corp at Nasdaq Investor Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at Nasdaq Investor Conference Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024